Navigation Links
Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Date:8/14/2013

Madison, VA (PRWEB) August 14, 2013

Carl Peck, MD, Chairman of NDA Partners LLC (NDAP), today announced that Sir Alasdair Breckenridge, former head of the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has joined NDA Partners as a partner in the firm. MHRA is the Department of Health agency responsible for regulating all medicines and medical devices marketed in the UK.

In his role at NDA Partners, Sir Alasdair will provide leadership for the firm’s expanding EU operations and expert consulting to its worldwide client base in complex and rapidly evolving topics such as health care policy, health technology assessment, reimbursements, EU clinical trials, global product development, global regulatory strategies, benefit-risk assessment, and bioethics. “Alasdair’s decades of experience at the forefront of drug development science and deep understanding of the global regulatory environment will be a tremendous asset for our clients as they seek the best available advice to guide their development programs”, said Dr Peck. “We look forward to Alasdair’s active involvement on our team and with our global client base”.

Sir Alasdair has a long and prestigious career in drug development science and regulatory affairs. He was the first Chair of MHRA when it was formed in 2003 and retained this position until his retirement from the Agency in 2012. During his tenure at MHRA, he served as the first Chair of the Department of Health's Emerging Science and Bioethics Advisory Committee (ESBAC), an organization responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council, worked closely on several programs of the European Union, the World Health Organization and the International Union of Pharmacology, and was Chair of the Committee on Safety of Medicines. Prior to MHRA, he was Professor of Clinical Pharmacology at the University of Liverpool and a member and then Chairman of local and regional health authorities in the north-west of England, including Chairman of the North West Regional Office. Sir Alasdair is a clinical pharmacologist and after training at the Royal Postgraduate Medical School, he was appointed to the Chair of Clinical Pharmacology at the University of Liverpool. Sir Alasdair was knighted in 2004.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11018273.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PharmaVentures Helps Secure Investor for Former MSD Research Site
5. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
6. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
7. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
8. Former Stryker CEO Takes Reins at sBioMed
9. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
10. Non-Intrusive Black Mold Removal Procedure Released By Former Mold Remediation Specialist, MyCleaningProducts.com Explains
11. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):